Not long ago, sophisticated medications that require precise temperature management during shipping were a small, specialized corner of the pharmaceutical industry. Today, they are its main driver of growth.
The rise of GLP-1 weight loss drugs has drawn significant attention, but even though they’re clearly the driver of this shift, they’re only one part of it. Alongside, although with somewhat less media fanfare, vaccines, biologics, gene therapies, and other high-value, temperature-sensitive specialty medicines are fueling rapid growth.
As these advanced therapeutics gain ground, the healthcare logistics market is expected to double by 2034. But with that growth come significant quality demands for supply chains.
New medications on the rise
GLP-1s have received a lot of attention for good reason. Drugs like Ozempic, Wegovy, and Zepbound now account for roughly 8% of all U.S. prescriptions. As of December 2025, 20% of U.S. households had at least one GLP-1 user, up from 9% in 2024. If you know somebody who’s recently lost a conspicuous amount of weight, this may very well be why.
But GLP-1s are just one class of novel drugs that are changing the way things are done in pharma logistics. The confluence of AI, genomics, and advanced biotech manufacturing has created the next generation of pharmaceuticals, including:
- Vaccines like the mRNA-based immunizations that saw their breakthrough during the pandemic
- Gene therapies that treat diseases by modifying or replacing genes
- CAR-T therapies, which reprogram immune cells to attack cancer
- Biologics derived from living cells or organisms and used to treat a variety of ailments, including cancer, autoimmune diseases, and genetic disorders
What these have in common, besides their benefits to the patient, is that they are all highly sensitive, expensive, subject to strict regulatory requirements, and require transportation within tightly controlled temperature ranges. This has made transporting them securely even more critical. What was once a niche capability is increasingly becoming a core requirement for pharmaceutical supply chains.
C.H. Robinson recently became one of just a handful of global logistics companies with more than $1 billion in healthcare revenue. Along the way, we have invested significantly in our temperature-controlled network as well as advanced quality control and security capabilities to stay ahead of the market’s growing needs.
Maintaining quality across a complex journey
Moving these medications is far more involved than simply shipping them in refrigerated containers. Many of them travel thousands of miles and cross borders before reaching pharmacies, clinics, or patients' homes. Along the way, they may move by truck, air cargo, and parcel networks. Success depends on every link in that chain functioning as intended. Each handoff creates opportunities for a cold chain breach or transit deviation.
To maintain product integrity, logistics providers must ensure:
- Consistent temperature management throughout the journey
- Real-time shipment monitoring and visibility
- Reliable chain-of-custody controls
- Secure handling
- Compliance with regulations across countries, states, and healthcare markets
New therapies create new supply chain challenges
To make matters more complicated, competition is growing for the same refrigerated air cargo containers, temperature-controlled trailers, and specialized warehouse space that are also used by food, beverage, chemical, and cosmetics manufacturers.
At the same time, distribution patterns are evolving. High-value, temperature-controlled drugs that once moved primarily to hospitals and clinics are increasingly reaching destinations including retail pharmacies and big box retailers that historically do not have extensive experience with such products, as well as patients' homes directly. That requires greater visibility, consistency, and coordination across a larger, more complex distribution network. The challenge is not any single piece of infrastructure. It’s maintaining control over the entire supply chain, without a single lapse.
At C.H. Robinson, we recently expanded our temperature-controlled and high-value capabilities by acquiring Despir Logistics, a specialized healthcare and life sciences transportation provider focused on shipments that demand the utmost security, visibility, and precision in execution.
As these next-gen medications grow in volume, we want to keep strengthening our capabilities for our customers—and for the patients who count on them.
This is only the beginning
Ultimately, the story of GLP-1s is about much more than weight loss. It is part of a broader wave of scientific innovation that is bringing more advanced therapeutics to market, improving patient outcomes, and creating entirely new kinds of global supply chains.
As advanced mRNA vaccines, biologics, gene therapies, and other temperature-sensitive medicines become more common, specialized healthcare logistics will only grow more important. The question for healthcare companies today is whether they’re equipped to meet those requirements. That will require partnerships with highly qualified logistics partners who can bring the scale and sophistication needed to provide end-to-end control. At C.H. Robinson, we stand ready to help.
